UnitedHealth's earnings visibility, unusually high dividend yield and resumed buybacks make paying under 16x forward earnings not look terrible. Still reasonably confident it is a good place to hide for long-term capital: Hemsley keeps clearing the bar, and UnitedHealth has beaten and raised guidance for three straight quarters. Further derisking remains a risk. x.com  x.com  x.com 

UnitedHealth's potential earnings recovery and margin expansion offer a fundamental case for its emerging Stage 2 uptrend. EPS is expected to grow 53%, from $20.47 in 2026 to $31.31 by 2029, while revenue is projected to rise from $448B to $511B; a weekly bull flag has broken out. x.com 

UnitedHealth's rebound still has a Medicaid problem because care costs are outpacing state funding. Q3 operating profit rose to $6.6bn from $4.3bn a year earlier, but Medicaid is still expected to lose money in 2026. x.com 

UnitedHealth remains essential to the US economy and still provides the best pay-and-collect mechanism for doctors and hospitals in the country. Per CNBC, its first-quarter adjusted EPS of $7.23 beat expectations of $6.57, and it raised its full-year earnings outlook. x.com 

UnitedHealth's Q2 confirms it is back to underpromising and overdelivering, removing any remaining doubt. Per the quoted results, adjusted EPS of $6.38 beat the $4.85 estimate, the medical cost ratio improved 270 bps to 86.7%, and full-year adjusted EPS guidance rose to $19.50-$20.00. CEO and congressional share purchases, plus Americans' need for the most important health insurer in the world, bode well for the company and the stock. x.com  x.com 

UnitedHealth is exposed as health insurance costs become unaffordable for employers: an industry that lives by price gouging will die by it. US employers face the largest health insurance cost hike since the Affordable Care Act began, with a 25% rise expected in 2027 after a massive drop in exchange enrollment. Employer-based health plans now look set to go the way of pensions and become extinct. x.com 

UnitedHealth collects ever-rising US healthcare spending, and its stock has stopped falling. Family plan costs rose 249% in two decades toward $24,000, US spending nears $10,000 a person, and the over-65 population is set to double to two billion by 2050. After earnings fell 59% and 69% in back-to-back quarters and the stock dropped from 606 to 248, it based near 250 for a year, a Weinstein Stage 1, then reclaimed its moving average and pushed above 400. x.com  x.com  x.com  x.com 

UnitedHealth may be making a rare episodic pivot for a stock its size, coming off an earnings beat. The stock is incredibly undervalued. x.com 

UnitedHealth's model is a conflict of interest, since it owns both the insurer and the doctors and data, which makes it too dark to own. It has been accused of using algorithms to systematically deny care to the elderly and sick to lift profits; as both the largest US employer of doctors and an insurer, the patient loses. The assassination of its CEO showed deep hostility toward that system. A moat built on denying care is not worth owning. x.com 

UnitedHealth should outperform through year-end on midterm-year seasonality and as a defensive leader if markets weaken. Over the last 20 years, healthcare has generally done well from July through December in midterm years, and if the S&P 500 rolls into a bear market, investors should rotate into defensives led by UNH. The bull case also rests on AI and GLP-1 use lowering the medical cost ratio and institutions returning to healthcare. The war has made everything more volatile. x.com